Are you satisfied with your looks? According to new GfK research, 60% of people in the United States said they are “completely” or “fairly” satisfied with their looks — slightly higher than the global average of 55%.
A retail pharmacy giant is beginning to fully harness the power of scale. Now firmly established as one of the top retailers of prescription drugs in the United States, Walmart may soon lay claim to an even bigger share of the pharmacy and OTC market as its leaders learn to align pharmacy operations and in-store marketing efforts more closely with other departments within Walmart’s Supercenters, discount stores and Neighborhood Markets.
A new and radically different concept for frontline health care emerged last year when Walmart unveiled its first Walmart Care Clinics in Texas, Georgia and South Carolina. If things go according to plan, patients and health plan payers across the United States can look forward to a cheaper and more affordable alternative to the family doctor for nearly all their primary care needs.
The retail behemoth that is Wal-Mart Stores Inc. is fixing its sights on a new target: the nation’s overstretched and overly costly primary healthcare system. The result could be a major disruption of that system and the acceleration of health reform in America.
While building a 4,500-store retail pharmacy powerhouse in the United States, Walmart also has kept pace with the specialty pharmacy revolution and is positioning itself to play a stronger role in this most innovative, dynamic and complex area of pharmaceutical R&D and bioengineering.
AB Acquisition LLC — parent company of Albertson's, New Albertson's and Safeway (collectively Albertsons) — has named industry veteran Mark Panzer as SVP of pharmacy, health and wellness, overseeing the company's 1,760 pharmacies in 34 states across the country.
Drug Store News on Sunday caught up with Brian McNamara, region head of Europe and the Americas of the recently christened GSK Consumer Healthcare, representing the joint venture between GlaxoSmithKline and Novartis to talk about what a consolidating OTC market means for the industry, and how GSK will be coming to market.